PAU6 Antibody

What is PAX6 and what are its primary biological functions?

PAX6 (paired box 6) is a transcription factor that plays crucial roles in the development of eyes, neural tissues, and pancreas. It functions in neurodevelopment and differentiation of islet cells in the pancreas . The protein consists of a paired domain and is involved in regulating specification of ventral neuron subtypes by establishing correct progenitor domains. PAX6 also competes with PAX4 in binding to common elements in glucagon, insulin, and somatostatin promoters . Additionally, it acts as a transcriptional repressor of NFATC1-mediated gene expression .

The PAX6 protein has a predicted molecular weight of 48 kDa, though it often appears at apparent molecular weights of 38, 40, 46, and 48 kDa in experimental conditions, suggesting potential post-translational modifications or isoforms .

What is PAUF and what is its significance in research?

PAUF (Pancreatic Adenocarcinoma Up-regulated Factor) is a protein that is overexpressed in pancreatic cancer but not in non-cancerous tissues . It plays important roles in carcinogenesis and metastasis. Research indicates that PAUF expression levels independently determine malignant behaviors of ovarian cancer cells . PAUF has been demonstrated to significantly increase tumor metastatic capacity, including migration, invasion, and adhesion in ovarian cancer cell lines .

What types of PAX6 antibodies are available for research?

Several types of PAX6 antibodies are available for research purposes:

The choice between these antibodies depends on the specific research application, target species, and experimental conditions required.

What applications are PAX6 antibodies suitable for?

PAX6 antibodies have been validated for numerous applications including:

• Western Blotting (WB)

• Immunohistochemistry (IHC) on paraffin-embedded tissues (IHC-P) and frozen sections (IHC-Fr)

• Immunofluorescence (IF)

• Flow Cytometry (FC/FACS)

• Chromatin Immunoprecipitation (ChIP)

• Immunoprecipitation (IP)

• Function Blocking experiments

• Gel Supershift assays

For example, the mouse monoclonal PAX6 antibody from DSHB has been confirmed effective across all these applications, making it a versatile tool for diverse research protocols .

What are the optimal storage conditions for PAX6 antibodies?

For PAX6 antibodies, storage recommendations typically include:

• Short-term storage (up to two weeks): 4°C

• Long-term storage: -20°C or -80°C in aliquots of no less than 20 μl

While many antibody products can maintain activity at 4°C for years, shelf-life at this temperature is highly variable. The DSHB PAX6 antibody contains the antimicrobial ProClin as a preservative . Other antibody formulations may use different preservatives, such as sodium azide (0.09%) with sucrose (2%) as seen in some preparations .

How should PAX6 antibodies be validated for specificity?

Validation of PAX6 antibody specificity should include:

• Western blot analysis: Verify the detection of bands at the expected molecular weights (approximately 38, 40, 46, and 48 kDa for PAX6) .

• Cross-reactivity testing: Confirm reactivity with the target species. For example, the DSHB PAX6 antibody has confirmed reactivity with multiple species including human, mouse, rat, zebrafish, amphibian, avian, fish, lizard, opossum, planaria, and turtle .

• Immunohistochemistry on known positive tissues: PAX6 is highly expressed in neural tissues and developing eye structures, making these appropriate positive controls.

• Inclusion of negative controls: Use tissues known not to express PAX6 or use secondary antibody-only controls.

• Blocking peptide competition: If the immunogen sequence is known, using the original peptide for competitive binding can confirm specificity.

What are the key considerations for using anti-PAUF antibodies in cancer research?

When using anti-PAUF antibodies in cancer research, researchers should consider:

• Expression levels: PAUF expression varies significantly between cancer cell lines. For instance, OVCAR-5 cell line expresses PAUF at much higher levels than other ovarian cancer cell lines .

• Functional validation: Knockout models (such as PAUF-knockout OVCAR-5) can serve as valuable negative controls for antibody specificity and for studying PAUF's biological functions .

• Therapeutic applications: Anti-PAUF antibodies like PBP1510 have demonstrated promising cancer growth inhibition in patient-derived xenograft studies and are being evaluated in clinical trials .

• Combined treatment approaches: Research indicates that anti-PAUF antibodies may have sensitizing and synchronizing effects when used in combination with other chemotherapeutic agents such as docetaxel .

• Dosage considerations: In clinical studies, dose-escalation designs are used to assess safety, tolerability, and efficacy of anti-PAUF antibodies at different concentrations .

How can PAX6 antibodies be utilized in developmental neurobiology research?

PAX6 antibodies are invaluable tools in developmental neurobiology research due to PAX6's critical role in neural development:

• Lineage tracing: PAX6 antibodies can identify specific neural progenitor populations during development, helping map neural differentiation pathways.

• Progenitor domain mapping: Since PAX6 regulates specification of ventral neuron subtypes by establishing correct progenitor domains, immunostaining with PAX6 antibodies can help characterize these domains spatially and temporally .

• Chromatin immunoprecipitation: PAX6 antibodies enable researchers to identify genomic binding sites of PAX6, elucidating its transcriptional regulatory networks in neural development .

• Functional blocking: Some PAX6 antibodies can be used in function-blocking experiments to study the immediate effects of PAX6 inhibition on developmental processes .

• Comparative developmental studies: The broad species cross-reactivity of some PAX6 antibodies (such as the DSHB antibody) allows for evolutionary developmental biology studies across diverse taxa .

What experimental approaches can be used to study PAUF's role in cancer progression?

Based on current research, several experimental approaches using PAUF antibodies can elucidate PAUF's role in cancer:

• Knockout models: PAUF-knockout cell lines (created through CRISPR-Cas9 or similar technologies) show significantly reduced metastatic capacity and slower proliferation rates. In the OVCAR-5 cell line, PAUF knockout resulted in 72% reduced migration and 68% reduced invasion compared to control cells .

• Recombinant PAUF supplementation: Adding recombinant PAUF to PAUF-knockout cells can reverse the loss of malignant traits, confirming PAUF's direct role in cancer progression .

• Xenograft tumor models: PAUF-knockout cancer cells in mouse models show delayed tumor growth. In BALB/c athymic nude mice, PAUF-knockout tumors took an average of 36 days to reach 500mm³ compared to 32 days in the control group .

• Antibody treatment: Anti-PAUF antibodies like PBP1510 can be administered as therapeutics in mouse models to assess tumor growth inhibition. These antibodies are also being tested in clinical trials for patients with advanced/metastatic pancreatic cancer .

• Combination therapy assessment: Anti-PAUF antibodies can be studied in combination with standard chemotherapeutics like gemcitabine to evaluate potential synergistic effects .

What are the considerations for using PAX6 antibodies in pancreatic development and disease studies?

PAX6 has significant roles in pancreatic development, particularly in islet cell differentiation:

• Lineage specification: PAX6 is required for the differentiation of pancreatic islet alpha cells, making PAX6 antibodies crucial for studying the development of these endocrine cells .

• Transcriptional regulation: PAX6 competes with PAX4 in binding to regulatory elements in glucagon, insulin, and somatostatin promoters, suggesting its importance in hormone expression regulation .

• Disease correlations: Changes in PAX6 expression may be linked to pancreatic disorders, including diabetes and pancreatic cancer. PAX6 antibodies can help quantify such expression changes in disease states.

• Co-localization studies: Combining PAX6 antibodies with markers for specific pancreatic cell types can reveal developmental relationships and cell-fate decisions during pancreatic organogenesis.

• Three-dimensional culture systems: PAX6 antibodies can help validate organoid models of pancreatic development by confirming appropriate expression patterns of this key transcription factor.

What are common challenges when using PAX6 antibodies in Western blotting?

When using PAX6 antibodies in Western blotting, researchers may encounter several challenges:

• Multiple band detection: PAX6 often appears as multiple bands (38, 40, 46, and 48 kDa), which might be misinterpreted as non-specific binding . Researchers should be aware of these multiple isoforms or post-translationally modified forms.

• Cross-reactivity: Some PAX6 antibodies may cross-react with related paired-box domain proteins. Proper controls, including PAX6-knockout samples when available, should be included.

• Optimal antibody concentration: Finding the optimal antibody dilution is critical. For example, some PAX6 antibodies are supplied at concentrations of approximately 0.5 mg/ml and require appropriate dilution for optimal signal-to-noise ratio.

• Blocking conditions: Optimization of blocking reagents (BSA vs. non-fat milk) may be necessary, especially when detecting phosphorylated forms of PAX6.

• Loading controls: As PAX6 is a nuclear protein, appropriate nuclear loading controls should be used rather than cytoplasmic housekeeping proteins.

How can researchers optimize immunohistochemical detection of PAX6 in different tissue types?

Optimization strategies for PAX6 immunohistochemistry include:

• Fixation methods: Different tissues may require different fixation protocols. For brain tissues, formalin fixation has been successfully used with PAX6 antibodies , but optimization may be needed for other tissue types.

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) is often effective for PAX6 detection, but this should be optimized for specific tissue types and fixation conditions.

• Antibody penetration: For thick tissue sections or whole-mount preparations, increasing incubation time or using detergents like Triton X-100 can improve antibody penetration.

• Signal amplification: For tissues with low PAX6 expression, signal amplification methods like tyramide signal amplification may be beneficial.

• Counterstaining: Appropriate nuclear counterstains that don't obscure PAX6 nuclear staining should be selected. DAPI at optimized concentrations is often suitable.

What protocol modifications are needed when using anti-PAUF antibodies in clinical samples?

When working with anti-PAUF antibodies in clinical samples, researchers should consider:

• Sample preparation: Clinical samples often require specific processing methods that may differ from cell lines. For example, FFPE (formalin-fixed paraffin-embedded) tissue samples require appropriate antigen retrieval methods.

• Expression heterogeneity: PAUF expression can be heterogeneous within tumors. Multiple sections or regions should be examined to account for this heterogeneity.

• Biomarker correlation: Anti-PAUF antibody staining should be correlated with other established biomarkers and clinical parameters to establish clinical relevance.

• Pre- and post-treatment analysis: When evaluating anti-PAUF therapies, comparing PAUF levels before and after treatment can provide valuable insights into therapeutic efficacy .

• Therapeutic antibody interference: In samples from patients receiving anti-PAUF therapeutic antibodies, detection of PAUF may be complicated by the therapeutic antibody binding to the same epitopes as the detection antibody. Using antibodies targeting different epitopes can mitigate this issue.

What are emerging applications of PAX6 and PAUF antibodies in research?

Emerging applications include:

• Single-cell analyses: PAX6 antibodies are increasingly being used in single-cell proteomics to understand heterogeneity in neural progenitor populations.

• Therapeutic development: Anti-PAUF antibodies like PBP1510 represent a promising new class of targeted cancer therapeutics currently in clinical trials .

• Combination biomarker panels: PAX6 and PAUF are being studied as part of broader biomarker panels for cancer diagnosis and prognosis.

• Organoid research: Both antibodies are valuable tools in the emerging field of organoid research, helping validate these 3D culture systems as models of development and disease.

• Cross-disciplinary applications: The wide species reactivity of some PAX6 antibodies enables comparative studies across evolutionary distant species, contributing to evolutionary developmental biology research .